Cost-Effectiveness of Digital HIV Self-Testing

By Crystal Lubbe

February 4, 2025

 Is digital innovation the key to enhancing HIV testing in high-prevalence regions? The article evaluates the cost-utility of digital HIV self-testing (HIVST) with digital supports in Malawi, South Africa, and Brazil. A Markov model compares the cost-effectiveness of digital HIVST to community-based and facility-based testing. Digital HIVST is cost-effective, especially for key populations with high HIV test-positivity rates. This approach improves linkage to care and ART initiation.

Key Insights on Digital HIV self-testing 

  • Cost-Effectiveness: Digital HIV self-testing is cost-effective compared to facility-based testing. ICERs range from $769 to $17,839 per DALY averted.
  • Linkage to Care: Linkage to care is crucial for cost-effectiveness. Required linkage rates vary from 20% to 48% by country.
  • Digital Supports: Text messaging and online platforms boost digital HIVST uptake, especially among hard-to-reach groups.
  • Country-Specific Outcomes: Cost-utility varies by country. Malawi has the lowest ICER, Brazil the highest, due to cost differences.
  • Key Drivers: Cost-utility drivers include HIVST cost, test-positivity rates, care linkage, and ART initiation rates.

Relevance to Global HIV Strategies

The study aligns with global HIV goals set by the United Nations, which aim to enhance HIV diagnosis and care by 2030. These goals emphasise innovative strategies, such as HIVST, to increase testing uptake. Previous studies have shown that HIVST can be cost-effective with community supports. However, there is limited data on the cost-utility of digital HIVST approaches. This study follows WHO CHOICE guidelines and uses GDP-based willingness-to-pay thresholds, a common method in health economic evaluations.

Implications for Health Policy and Research

The findings suggest that digital HIVST is a highly cost-effective method for increasing HIV testing and improving care linkage, particularly in regions with high HIV prevalence and limited access to conventional testing. Policymakers should consider incorporating digital HIVST into their testing strategies, focusing on key populations with high rates of undiagnosed HIV. Strategies to enhance cost-utility include ensuring adequate linkage to care, negotiating reduced test costs, and leveraging digital technologies to improve accessibility. While digital HIVST offers many benefits, it may not suit all populations due to disparities in internet and device access. A balanced approach that combines digital and traditional methods is essential to ensure health equity.

Further research is needed to assess the long-term impact of HIVST on community HIV incidence and the cost-effectiveness of various digital strategies. Addressing limitations in current studies, such as the lack of dynamic transmission modeling and limited costing data for digital HIVST, is also vital.

Reference url

Recent Posts

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

essential prescription drugs
       

Canada Launches Consultation for Essential Prescription Drugs List

💊 Are you curious about how Canada plans to make essential prescription drugs accessible for everyone?

Canada’s Drug Agency has launched a national consultation to create a list of essential prescriptions that aim to ensure equitable access, improve health outcomes, and reduce costs. This initiative marks a key step towards universal pharmacare and highlights the importance of evidence-based practices in healthcare.

Dive into our latest article to learn more about the implications for patients, policymakers, and the broader healthcare system!

#SyenzaNews #healthcare #HealthEconomics

ACIP vaccine policy concerns
     

ACIP Vaccine Policy Concerns

🛑 Is the future of vaccine policy at risk?

The recent overhaul of the US Advisory Committee on Immunization Practices (ACIP) raises critical concerns about the integrity and transparency in vaccine recommendations. The abrupt removal of longstanding members may disrupt the essential processes that have historically upheld public trust and immunization success.

Curious about the implications for health policy and public health? Dive into the full analysis to understand the balance needed between continuity and reform!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.